Reports and Releases
Resolutions by FIT Biotech Oy’s extraordinary general meeting on 22 October 2015 relating to the composition of the board of directors
FIT Biotech Oy
Company Release, October 22, 2015 at 16:00 EET
Resolutions by FIT Biotech Oy's extraordinary general meeting on 22 October 2015 relating to the composition of the board of directors
The extraordinary general meeting of FIT Biotech Oy has today decided to increase the number of the members of the board of directors so that there are six (6) ordinary members at the board.
In addition, the general meeting decided to elect Tomi Numminen and Rabbe Klemets as new members of the board of directors. In other respects, the composition of the board of directors will remain unchanged, i.e. current members of the board Rabbe Slätis, Erkki Pekkarinen, Dirk Teuwen and Juha Vapaavuori will continue as ordinary members of the board of directors. Rabbe Slätis will continue as the chairman of the board.
Chairman of the board Rabbe Slätis: "We are extremely pleased to welcome to the board of directors professionals with solid industry expertise and strong track-records of developing companies in the sector."
FIT Biotech Oy
Board of Directors
Chairman of the board Rabbe Slätis, FIT Biotech Oy
Phone: +358 40 840 6749
Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790
FIT Biotech Oy in brief:
FIT Biotech Oy is a biotechnology company established in 1995, focusing on DNA vaccines and gene therapy. The company bases its products on its patented GTU ® (Gene Transport Unit) technology.
Through GTU technology, FIT Biotech develops DNA vaccines in order to both prevent and also treat various diseases. Identified application areas include HIV, tuberculosis (and other infectious diseases) as well as gene therapy (cancer, autoimmune diseases). Other application areas are under development.
FIT Biotech Oy is listed on NASDAQ First North (ticker: FITBIO). More information can be found at www.fitbiotech.com.
NASDAQ OMX Helsinki